“…For the most part, glycomodified plants have been created through RNAi gene-silencing technology, mainly owing to the existence of multiple endogenous fucosyltransferase and xylosyltransferase genes in most plants (Cox et al, 2006;Sourrouille et al, 2008;Strasser et al, 2008). Although it is generally believed that P19 cannot reverse established gene-silencing pathways (Scholthof, 2006), interference in the siRNA pathway by P19 becomes a concern when RNAi-generated genetic backgrounds are to be used as expression hosts for producing therapeutic proteins, primarily because there are not reports in the literature on using P19 with an RNAi-based glycomodified host, but also since in an unrelated case, P19 was shown to repress the knockdown of a previously established RNAi transgenic line (Ahn et al, 2011). With the above-discussed results in mind, we present a series of experiments that demonstrate how P19 can be used effectively to enhance the expression of a recombinant therapeutic glycoprotein, such as a biosimilar therapeutic antibody, in plant-based expression systems.…”